Obesity

UK major will bag CSPC’s eight preclinical drug candidates in weight management, including most advanced asset SYH2082, a long-acting GLP-1/GIP receptor agonist with once-monthly dosing potential.

Conclusion of India-EU talks sets ground for a free trade agreement to cut pharma tariffs, in turn lowering the cost for novel drugs like Novo’s obesity treatment Wegovy, though an investment protection agreement – likely influencing data exclusivity – will be concluded later.

Sun Pharma’s generic Wegovy product has cleared regulatory review, positioning the company to enter India’s obesity drug market once patent protection lapses.

In line with previously disclosed launch and partnering plans for GLP-1 products, Lupin shook hands with Galenicum, securing commercial rights to injectable semaglutide.

Dr Reddy’s gears for semaglutide debut across markets, including India and Canada, where Novo Nordisk has second brands of the GLP-1 agonist potentially ready. Can the Indian group close out compliance queries from the Canadian regulator soon?

Amid Pfizer’s acquisition of Metsera and Hanmi’s novel contender moving to the approval stage, South Korean obesity assets are poised to attract more interest from global pharma firms and investors.

A search bar has become one of the most powerful gateways into modern healthcare. The result is a gray zone where advertising practices, consumer trust and public health collide, raising questions about whether digital marketing has outpaced regulation.

2025 saw star products debut in India as foreign firms doubled down on high-value, IP-protected therapies. Experts tell Scrip the top 10 cities in the country can now sustain “US/EU-style” specialty launches.

There has not been a dull moment in the biopharma sector this year. With just a day left, and in no particular order, Scrip takes a look at five of the biggest stories of 2025.

The Korean biopharma industry in 2025 was marked by some major deals involving smaller companies, while the improving investment climate could see further activity in selected areas in 2026.

The obesity field is entering the “sobering” phase of the hype cycle; GLP-1 drugs have opened the door but have limitations. Aphaia CSO Steffen-Sebastian Bolz talks to In Vivo about shifting the focus back to patient experience, not just maximal weight loss.

Decision matches earlier Dr Reddy’s outcome, although no injunctive action involved, allowing exports to non-patent markets ahead of a post-expiry launch.